The significant reductions in plasma IL-6 levels after 6-months in the HT group points to the possibility that elderly adults with inflammatory diseases associated with high IL-6 levels such as depression, dementia, rheumatoid arthritis and cancer could garner benefits from HT. This evidence concerns the gene IL6 and depressive symptom measurement.